Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)

Inclusion Criteria:

• Meets listed criteria for a diagnosis of probable AD
• Has a clearly documented history either in medical records or from an informant of cognitive decline over at least 6 months
• Has a reliable partner/caregiver who is willing to provide input by participating in assessments
• Has results of a physical examination and clinical laboratory tests within normal or clinically acceptable limits
• Can communicate with trial staff acceptably, possesses the ability to respond verbally to questions, follow instructions, complete questionnaires, and adhere to visit schedules
• Can read at a 9th grade level or equivalent, and has an acceptable history of academic achievement and/or employment
• Has a magnetic resonance imaging (MRI) scan that rules out non-AD conditions contributing to cognitive dysfunction
• Capably performs the CogState screening battery
• Has adequate visual acuity and function
• Females are not of childbearing potential

Exclusion Criteria:

• Has ever received acetylcholinesterase inhibitors, memantine, or other symptomatic AD treatment including approved medical foods
• Has an uncontrolled, clinically significant medical condition or situation within 3 months prior to screening
• Has had major surgery within 3 months prior to screening
• Has tested positive for human immunodeficiency virus (HIV) or has evidence of an active hepatitis B infection
• Has a history of malignancy within the prior 5 years
• Is unwilling or ineligible to undergo an MRI scan
• Has a history of clinically important structural changes on screening MRI scan
• Has a clinically important history of stroke or a diagnosis of vascular dementia
• Has evidence of a clinically relevant non-AD neurological disorder
• Has a history of head trauma, or serious infectious disease affecting the brain within the prior 3-5 years
• Has evidence of a clinically relevant or unstable psychiatric disorder, excepting major depression in remission
• Has evidence of a current episode of major depression
• Has evidence of Type 4 or Type 5 Suicidal Ideation
• Has clinically significant vitamin B12 or folate deficiency in the 6 months prior to screening
• Is pregnant, attempting to become pregnant or is nursing children
• Has used any investigational drug or participated in any other clinical trial within the prior 30 days
• Has a history of alcoholism or drug dependency/abuse within the last 5 years
• Has a relative contraindication to donepezil including sick sinus syndrome, third degree heart block, active gastrointestinal (GI) bleeding, Zollinger-Ellison syndrome, uncontrolled peptic ulcer disease, or uncontrolled asthma